JP Morgan's lowered price target on CVS Health may have a neutral short-term impact on the stock price. While the Overweight rating indicates a positive outlook, the reduced price target may cause some investors to reevaluate their positions. However, the overall sentiment remains positive, which is why the score is neutral.